2023
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update
Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023, 83: 217-248. PMID: 36645621, DOI: 10.1007/s40265-023-01835-2.Commentaries, Editorials and LettersConceptsNeck cancerRecurrent/metastatic settingImmune checkpoint inhibitor nivolumabNeck squamous cell carcinomaAge of immunotherapyLate stage HNSCCImmune checkpoint inhibitionPlatinum-containing chemotherapyFirst-line treatmentGrowth factor receptor overexpressionCheckpoint inhibitor nivolumabSquamous cell carcinomaEpidermal growth factor receptor (EGFR) overexpressionPathogenesis of HNSCCTreatment of patientsTreatment of HNSCCManagement of headMonoclonal antibody cetuximabCurative intentPalliative chemotherapyAdvanced diseaseInhibitor nivolumabLocoregional failureMetastatic settingMultimodality therapy
2021
Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review
Hayman TJ, Bhatia AK, Jethwa KR, Young MR, Park HS. Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review. Translational Cancer Research 2021, 10: 2571-2585. PMID: 35116571, PMCID: PMC8798834, DOI: 10.21037/tcr-20-2096.Peer-Reviewed Original ResearchNeck squamous cell carcinomaSquamous cell carcinomaRadiation therapyCell carcinomaImmune responseNon-surgical treatment modalitiesCell death ligand 1Cell death protein 1Cancer-directed therapyCombination of immunotherapyAnti-tumor responseDeath ligand 1Death protein 1Adaptive immune responsesAdaptive immune systemAdvanced HNSCCAdvanced diseaseMetastatic settingPostoperative settingSystemic therapyImmunomodulatory effectsTreatment modalitiesRecurrent/Clinical trialsClinical data